Warner Chilcott PLC was hit with a class action on Friday alleging the drugmaker violated U.S. antitrust laws when it agreed to settle “sham” patent infringement litigation against Lupin Pharmaceuticals Inc. and Watson Pharmaceuticals Inc. that delayed entry of generic versions of oral contraceptive Loestrin.
